Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지

Treatment of Chronic Myofascial Pain with Botulinum Toxin : Case Report

보툴리눔 톡신을 이용한 만성 근막통증의 치료 증례

  • Hong, Seong-Ju (Department of Oral medicine, School of Dentistry, Chosun University) ;
  • Yoon, Chang-Lyuk (Department of Oral medicine, School of Dentistry, Chosun University) ;
  • Ahn, Jong-Mo (Department of Oral medicine, School of Dentistry, Chosun University) ;
  • Ryu, Ji-Won (Department of Oral medicine, School of Dentistry, Chosun University)
  • 홍성주 (조선대학교 치과대학 구강내과학교실) ;
  • 안종모 (조선대학교 치과대학 구강내과학교실) ;
  • 윤창륙 (조선대학교 치과대학 구강내과학교실) ;
  • 유지원 (조선대학교 치과대학 구강내과학교실)
  • Received : 2010.05.21
  • Accepted : 2010.06.15
  • Published : 2010.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

MyoFascial Pain Syndrome(MFPS) is defined as a regional pain syndrome characterized by muscle pain caused by myofascial trigger points (MTrPs). Myofascial pain is a common cause of persistent regional pain such as neck pain, shoulder pain, headaches, and orofacial pain. Clinicians who deal with orofacial pain must also understand the role of myofascial pain. This case report presents the treatment of botulinum toxin A for chronic myofascial pain.

근막통증은 발통점에 의해 야기되는 근육통을 특징으로 하는 전반적인 통증 증후군으로 정의될 수 있다. 근막통증은 경부통, 견통, 두통 및 구강안면통증이 지속적으로 존재할 수 있는 흔한 원인이 될 수 있다. 구강안면통증을 치료하는 의사들은 근막통증이 구강안면통증에 기여하는 바에 대하여 이해하고 있어야 한다. 본 증례는 보툴리눔 톡신 A형을 이용한 만성 근막통증의 성공적인 치료에 대하여 보고하고자 한다.

Keywords

References

  1. Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanism of myofascial trigger points. Arch Phys Med Rehabil 1998;79:863-872. https://doi.org/10.1016/S0003-9993(98)90371-9
  2. Simons DG, Travell JG, Simons LS. Travell & Simons's Myofascial Pain and Dysfunction: The Trigger Point Manual. 2nd edi., Baltimore, 1999,Williams & Wilkins, pp. 11-86.
  3. Fleckenstein J, Zaps D, Ruger LJ, et al. Discrepency between prevalence and perceived effectiveness of treatment methods in myofascial pain syndrome: Results of a cross-sectional, nationwide survey. BMC Musculoskelet Disord 2010;11:32-41. https://doi.org/10.1186/1471-2474-11-32
  4. Svensson P, List T, Hector G. Analysis of stimulusevoked pain in patients with myofascial temporomandibular pain disorders. Pain 2001;92:399-409. https://doi.org/10.1016/S0304-3959(01)00284-6
  5. Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60:615-623. https://doi.org/10.1016/0030-4220(85)90364-0
  6. Fricton JR. Myofascial pain: clinical characteristics and diagnostic criteria. J Musculoskel Pain 1993;1: 37-47.
  7. Han SC, Harrison P. Myofascial pain syndrome and triggerpoint management. Reg Anesth 1997;22:89-101. https://doi.org/10.1016/S1098-7339(06)80062-3
  8. Stohler CS. Masticatory myalgias. In Oral and Maxillofacial Surgery. Temporomandibular Disorders. Philadelphia, 2000, WB Saunders, pp.38 - 45.
  9. Piovesan EJ, Werneck LC, Teive HA, et al. Neurophysiology of pain in tentorial irritation: description of a case secondary to medulloblastoma. Arq Neuropsiquiatr 1998;56:677-682. https://doi.org/10.1590/S0004-282X1998000400027
  10. Hutchinson PJ, Pickard JD, Higgins JN. Vertebral artery dissection presenting as cerebellar infarction. J Neurol Neurosurg Psychiatry 2000;68:98–99. https://doi.org/10.1136/jnnp.68.1.98
  11. Aoki KR. Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. NeuroToxicology 2005;26:785 - 793. https://doi.org/10.1016/j.neuro.2005.01.017
  12. Rand J, Whaler BC. Impairment of sympathetic transmission by Botulinum toxin. Nature 1965;206:588 - 591. https://doi.org/10.1038/206588a0
  13. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jawmuscle spindles. Acta Otolaryngol 1993;113:400 - 404. https://doi.org/10.3109/00016489309135834
  14. Jankovic J, Tintner R. Botulinum toxin for the treatment of cervical dystonia. Expert Opinion 2001;2:1985 - 1994. https://doi.org/10.1517/14656566.2.12.1985
  15. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with Botulinum toxin A: A short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005;84:649 - 654. https://doi.org/10.1097/01.phm.0000176339.73591.d7
  16. Abbott JA, Jarvis SK, Lyons SD, Thompson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: A randomized controlled trial. Obstet Gynecol 2006;108:915 - 923. https://doi.org/10.1097/01.AOG.0000237100.29870.cc
  17. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research group. Headache 2000;40:445 - 450. https://doi.org/10.1046/j.1526-4610.2000.00066.x
  18. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. Neurology 2001;56:1290 - 1293. https://doi.org/10.1212/WNL.56.10.1290
  19. Steinder A. The interpretation of the sciatic radiation and the syndrome of low back pain. J Bone Joint Surg 1940;22:28-34.
  20. Graff-Radford SB. Regional myofascial pain syndrome and headache: principles of diagnosis and management. Curr Pain Headache Rep 2001;5(4): 376-381. https://doi.org/10.1007/s11916-001-0028-8
  21. Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point Manual. Baltimore, 1983, Williams and Wilkins, pp 24-25.
  22. Graff-Radford SB. Myofascial pain: diagnosis and management. Curr Pain Headache Rep 2004;8: 463-467. https://doi.org/10.1007/s11916-004-0068-y
  23. Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60:615 - 623. https://doi.org/10.1016/0030-4220(85)90364-0
  24. Majlesi J, Unalan H. Effect of treatment on trigger points. Curr Pain Headache Rep 2010;14(5):353-360. https://doi.org/10.1007/s11916-010-0132-8
  25. Sharav Y, Singer E, Schmidt E, et al.: The analgesic effect of amitriptyline on severe facial pain. Pain 1987;31:199-203. https://doi.org/10.1016/0304-3959(87)90036-4
  26. Tsuga K, Akagawa Y, Sakaguchi R, Tsuru H. A short-term evaluation of the effectiviness of stabilisation therapy for specific symptoms of temporomandibular joint dysfunction syndrome. J Prosthet Dent 1989;61:610-613. https://doi.org/10.1016/0022-3913(89)90286-2
  27. Gray RJM, Davies SJ, Quale AA. A comparison of two splints in the treatment of TMJ myofascial pain: can occlusal analysis be used to predict success of splint therapy? Br Dent J 1991;170:257-261. https://doi.org/10.1038/sj.bdj.4807487
  28. Davies SJ, Gray RJM. The pattern of splint usage in the management of two common temporomandibular disorders. Part III: Long-term follow-up in an assessment of splint therapy in the management of disc displacement with reduction and pain dysfunction syndrome. Br Dent J 1997;183:279-283. https://doi.org/10.1038/sj.bdj.4809495
  29. Al-Ani Z, Gray RJ, Davies SJ, Sloan P, Glenny AM. Stabilization splint therapy for the treatment of temporomandibular myofascial pain: a systematic review. J Dent Educ 2005;69(11):1242-1250.
  30. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599 - 608.
  31. Tarsy D, First ER. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 1999;14:1043 - 1045. https://doi.org/10.1002/1531-8257(199911)14:6<1043::AID-MDS1026>3.0.CO;2-3
  32. Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 2010; 23(5):602-610. https://doi.org/10.1097/ACO.0b013e32833c3405
  33. Kerr FW. A mechanism to account for frontal headache in cases of posterior fosse tumors. J Neurosurg 1961;18:605-609. https://doi.org/10.3171/jns.1961.18.5.0605
  34. Piovesan EJ, Werneck LC, Teive HA, et al. Neurophysiology of pain in tentorial irritation: description of a case secondary to medulloblastoma. Arq Neuropsiquiatr 1998;56:677-682. https://doi.org/10.1590/S0004-282X1998000400027
  35. utchinson PJ, Pickard JD, Higgins JN: Vertebral artery dissection presenting as cerebellar infarction. J Neurol Neurosurg Psychiatry 2000;68:98-99. https://doi.org/10.1136/jnnp.68.1.98
  36. Piovesan EJ, Kowacs PA, Oshinsky ML. Convergence of cervical and trigeminal sensory afferents. Curr Pain Headache Rep 2003;7(5):377-83. https://doi.org/10.1007/s11916-003-0037-x